China FDA Set To Greenlight First Domestic Lymphoma Drug
This article was originally published in PharmAsia News
On the verge of obtaining its first new drug approval from the China FDA to treat a rare cancer type, Chinese domestic biotech ChipScreen is poised to benefit from an increasingly confident regulatory agency.
You may also be interested in...
San Diego's Huya Signs Six New Deals With Chinese Scientific Partners, Looks To Fast Forward Global Drug Development
BEIJING - During a whirlwind tour of China, the leaders of the San Diego-headquartered Huya Bioscience have signed, in rapid succession, partnership pacts with prestigious scientific institutions in half a dozen cities on drug research and development
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.